Searched for: subject:"Protein%5C%2BBinding"
(1 - 10 of 10)
document
Gaubius Instituut TNO (author), Nguyen, M.T. (author), Beck, J. (author), Lue, H. (author), Fünfzig, H. (author), Kleemann, R. (author), Koolwijk, P. (author), Kapurniotu, A. (author), Bernhagen, J. (author)
Macrophage migration inhibitory factor (MIF) is a cytokine that participates in the host inflammatory response. A Cys-Xaa-Xaa-Cys (CXXC)-based thiol-protein oxidoreductase activity of MIF is associated with certain biological functions. Peptides spanning the CXXC region of thiol-protein oxidoreductases retain some biochemical properties of the...
article 2003
document
Gaubius Instituut TNO (author), Walker, J.B. (author), Hughes, B. (author), James, I. (author), Haddock, P. (author), Kluft, C. (author), Bajzar, L. (author)
Two competitive inhibitors of TAFIa (activated thrombin-activable fibrinolysis inhibitor), 2-guanidinoethyl-mercaptosuccinic acid and potato tuber carboxypeptidase inhibitor, variably affect fibrinolysis of clotted human plasma. Depending on their concentration, the inhibitors shortened, prolonged, or had no effect on lysis in vitro. The...
article 2003
document
Gaubius Instituut TNO (author), de Man, F.H.A.F. (author), de Beer, F. (author), van der Laarse, A. (author), Smelt, A.H.M. (author), Havekes, L.M. (author)
An in vitro assay to study lipolysis of very low density lipoproteins (VLDL) by heparan sulfate proteoglycan (HSPG-bound lipoprotein lipase (LPL) was developed. Optimal conditions for VLDL lipolysis by HSPG-bound LPL were obtained by incubating plastic wells with 0.5 ug HSPG and 1.5 ug LPL, subsequently. Control experiments with heparinase...
article 1997
document
Gaubius Instituut TNO (author), Sakharov, D.V. (author), Lijnen, H.R. (author), Rijken, D.C. (author)
Staphylokinase (STA), a protein of bacterial origin, induces highly fibrin-specific thrombolysis both in human plasma in vitro and in pilot clinical trials. Using fluorescence microscopy, we investigated the spatial distribution of fluorescein isothiocyanate (FITC)-labeled STA during lysis of a plasma clot and its binding to purified fibrin...
article 1996
document
Gaubius Instituut TNO (author), Mulder, M. (author), Lombardi, P. (author), Jansen, H. (author), van Berkel, T.J.C. (author), Frants, R.R. (author), Havekes, L.M. (author)
It has previously been shown that lipoprotein lipase (LPL) enhances the binding of low density lipoproteins (LDL) and very low density lipoproteins (VLDL) to HepG2 cells and fibroblasts, up to 80-fold. This increase in binding is LDL receptor-independent and is due to a bridging of LPL between extracellular heparan sulfate proteoglycans (HSPG)...
article 1993
document
Gaubius Instituut TNO (author), Kluft, C. (author), Jie, A.F.H. (author), Sprengers, E.D. (author), Verheijen, J.H. (author)
Inhibition of tissue-type plasminogen activator (t-PA) by pooled plasma could be ascribed for only 60% to the endothelial cell type PA inhibitor. The residual inhibition is ascribed to a so-far undescribed plasma component present at 0.2 nmol/l. This component shows reversible binding to t-PA with an apparent K(i) of 10 pmol/l (does not hinder t...
article 1985
document
Gaubius instituut TNO (author), Havekes, L. (author), van Hinsbergh, V. (author), Kempen, H.J. (author), Emeis, J. (author)
The human hepatoma cell line Hep G2 was studied with respect to metabolism of human low-density lipoprotein (LDL). The Hep G2 cells bind, take up and degrade human LDL with a high-affinity saturable and with a low-affinity non-saturable component. The high-affinity binding possesses a K(D) of 25 nM-LDL and a maximal amount of binding of about 70...
article 1983
document
Nieuwenhuizen, W. (author), Voskuilen, M. (author), Hermans, J. (author), Gaubius instituut TNO (author)
The present study was undertaken as a step to delineate further the localization of the calcium-binding sites in fibrinogen and to assess the anticlotting properties of fibrinogen degradation products. To this purpose, fragments Y were prepared by plasmin digestion of human fibrinogen in the presence of added Ca2+, and purified. We found that,...
article 1982
document
Gaubius Instituut TNO (author), Nieuwenhuizen, W. (author), Vermond, A. (author), Nooijen, W.J. (author), Haverkate, F. (author)
Here the results obtained with human fibrinogen and its degradation products are reported. Our results differ from those obtained in (9) but strongly support model suggested earlier by us for Ca2(+)-binding by rat fibrinogen. Chemicals/CAS: calcium, 7440-70-2; fibrin, 9001-31-4; fibrinogen, 9001-32-5; Calcium, 7440-70-2; Fibrin, 9001-31-4;...
article 1979
document
Gaubius instituut TNO (author), van Ruijven-Vermeer, I.A.M. (author), Nieuwenhuizen, W. (author), Nooijen, W.J. (author)
The authors studied the binding of Ca to rat fibrinogen and plasmic fibrin(ogen) degradation products by means of equilibrium dialysis with special reference to the protective effect of Ca2+ in the plasmic degradation of fibrinogen. Direct binding studies demonstrate that rat fibrinogen and the plasmic degradation products D(cate) and D-dimer...
article 1978
Searched for: subject:"Protein%5C%2BBinding"
(1 - 10 of 10)